Advertisement

Topics

Latest "Colon Cancer Pipeline Review 2017 Report Updated 30062017" News Stories

21:40 EDT 20th March 2019 | BioPortfolio

Here are the most relevant search results for "Colon Cancer Pipeline Review 2017 Report Updated 30062017" found in our extensive news archives from over 250 global news sources.

More Information about Colon Cancer Pipeline Review 2017 Report Updated 30062017 on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Colon Cancer Pipeline Review 2017 Report Updated 30062017 for you to read. Along with our medical data and news we also list Colon Cancer Pipeline Review 2017 Report Updated 30062017 Clinical Trials, which are updated daily. BioPortfolio also has a large database of Colon Cancer Pipeline Review 2017 Report Updated 30062017 Companies for you to search.

Showing "Colon Cancer Pipeline Review 2017 Report Updated 30062017" News Articles 1–25 of 47,000+

Wednesday 20th March 2019

[The Lancet Commissions] Building a tuberculosis-free world: The Lancet Commission on tuberculosis

Tuberculosis can be treated, prevented, and cured. Rapid, sustained declines in tuberculosis deaths in many countries during the past 50 years provide compelling evidence that ending the pandemic is feasible. Yet this disease—which has plagued humanity since before recorded history and has killed hundreds of millions of people over the past two centuries—remains a relentless scourge. In 2017, ...


[Comment] Building a tuberculosis-free world on a foundation of universal health coverage

It is a sad indictment of our unequal world that in 2019 we need a Lancet Commission on building a tuberculosis-free world.1 As the authors of this excellent Commission highlight in their first sentence: “tuberculosis can be treated, prevented, and cured”. However, despite progress in some countries, which shows the epidemic can be beaten, this ancient disease continues to kill more people tha...

[World Report] Inuit research raises concerns about tuberculosis eradication

Although Canada is on track to meet the eradication goals for tuberculosis set by the high-level meeting, Indigenous communities are still disproportionately affected. Paul Webster reports.


3SBio Unveils 2018 Annual Results: Revenue Soars by 22.7%, Normalized Net Profit Soars by 29.0%, R&D Expenses Jumps Over 40%

HONG KONG, March 21, 2019 /PRNewswire/ -- Chinese leading biotechnology company 3SBio (01530.HK) today released its 2018 annual results, showing that the Company has been posting dramatic business growth, and has been gearing up R&D layout and investment in innovative drugs. Financial highlights showed that the Company's revenue increased by approximately 22.7% to approximately RMB 4,583.9 m...

Genomics England and Cambridge Cancer Genomics (CCG.ai) announce immunotherapy partnership

CAMBRIDGE, United Kingdom, March 20, 2019 (GLOBE NEWSWIRE) -- Genomics England, the Department of Health and Social Care’s genomics spin-out, and Cambridge Cancer Genomics (CCG.ai), a precision AI platform company, announced today a broad partnership to improve UK-patient access to immune-system modulating cancer drugs (immunotherapies), monitor treatment effectiveness over time, and rapidly ...

Response to Letter to the Editor by Dr Cao regarding paper titled - “Is body-weight-supported treadmill training or robotic-assisted gait training superior to overground gait training and other forms of physiotherapy in people with spinal cord injury? A

Letter to the Editor: “Is body-weight-supported treadmill training or robotic-assisted gait training superior to overground gait training and other forms of physiotherapy in people with spinal cord injury? A systematic review”

New report finds applying an ICER-like standard in Medicaid would limit access to more than 820,000 prescriptions for medicines that treat cancer, MS and more. https://catalyst.phrma.org/new-analysis-shows-820000-prescriptions-would-be-in-jeopardy-if-ic

New report finds applying an ICER-like standard in Medicaid would limit access to more than 820,000 prescriptions for medicines that treat cancer, MS and more. https://catalyst.phrma.org/new-analysis-shows-820000-prescriptions-would-be-in-jeopardy-if-icers-value-framework-is-used-in-medicaid …

Cancer-associated fibroblasts enhance tumor-associated macrophages enrichment and suppress NK cells function in colorectal cancer

BriaCell Announces $2,000,000 Non-Brokered Private Placement Offering

BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is pleased to announce that it intends to complete a non-brokered private placement of up to 20,000,000 common shares of the Company at a price of C$0.10 per common share for gross proceeds of up to approximat...

Aeroflow Healthcare to Host April Diaper Drive to Benefit Diaper Bank of North Carolina

Aeroflow Healthcare, an Inc. 5000 fastest growing company, today announced that its Urology division will host a diaper drive from April 22-26, during national Every Kid Healthy™ Week, to benefit Diaper Bank of North Carolina. ASHEVILLE, N.C. (PRWEB) March 20, 2019 Aeroflow Healthcare, an Inc. 5000 fastest growing company, today announced that its Urology division will host a diaper drive from ...

City of Hope Awarded $7.5 Million to Develop Better Treatment for a Rare, Incurable Cancer

The institute’s multidisciplinary cutaneous lymphoma program has given hope to countless patients who suffer from the disfiguring disease. City of Hope recently received $7.5 million in grant awards to study a rare type of blood cancer that affects the skin: cutaneous T cell lymphoma (CTCL). The National Cancer Institute (NCI) awarded two gr...

As Exact Sciences’ Sales Surge, CEO Reflects on 10-Year Turnaround

A decade ago, Kevin Conroy took the CEO job at Exact Sciences, a cancer diagnostic firm on the brink of death. Five years later, the FDA greenlit the company’s first product, Cologuard, which marked the first non-invasive, stool-based DNA screening test approved for detecting colorectal cancer. In the five years since then, Exact (NASDAQ: EXAS) […]

CynergisTek, Inc. Sells Managed Print Services Business to Vereco, LLC for $30 Million

Deal Allows CynergisTek to Become Pure Play Cybersecurity Company CynergisTek, Inc., (NYSE AMERICAN: CTEK), a leader in healthcare cybersecurity, privacy, and compliance, today announced that it has closed a transaction to sell the assets used in its Managed Print Services (MPS) business division for $30 million to Vereco, LLC, a leading independe...

HealthWarehouse.com Reports Full Year 2018 Results

Core consumer prescription year-over-year net sales grow 16%;Automation investment leads to record service levels HealthWarehouse.com, Inc. (OTC: HEWA) announced today that its net sales for 2018 increased 6% to $15,748,162 compared to $14,847,262 in 2017. The 2018 annual results benefited from a strong fourth quarter during which net sales i...

How One Startup Plans To Win Primary Care Battle In China

Millions of people lack access to quality healthcare services and products in China, but now one company has raised millions...   

Alexion Inks Collaborations Totaling $1.3B+ with Affibody, Zealand

Alexion Pharmaceuticals today announced a pair of collaborations totaling potentially more than $1.3 billion—one partnership aimed to co-developing an autoimmune disease treatment, and another aimed at expanding Alexion’s pipeline into peptide therapies. Alexion agreed to co-develop Affibody’s Phase I bivalent antibody-mimetic ABY-039 for rare Immunoglobulin G (IgG)-mediated autoimmune disea...

Trastuzumab Tied to Higher Long-Term Risk for Heart Failure

WEDNESDAY, March 20, 2019 -- Compared with chemotherapy alone, trastuzumab is associated with a twofold increased long-term risk for heart failure in breast cancer survivors, according to a study published in the March 1 issue of JACC: Heart...

Jury Finds Roundup a Major Contributor to Man's Cancer

WEDNESDAY, March 20, 2018 -- Monsanto's Roundup weedkiller was a major factor in a California man's cancer, a federal jury in San Francisco has ruled. The decision in Edwin Hardeman's case is a landmark verdict that could impact hundreds of other...

BRCA1 as a stress coach in neuroblastoma

Anyone who has ever studied the molecular basis of breast cancer will probably have heard of the abbreviation BRCA1 - this is a protein that protects the cells of breast tissue against cancer. Surprisingly, this protein can also have an opposite effect:...

-23andMe to offer genetic reports on #diabetes -Dutch pharmacists dodge #Novartis #cancer drug market exclusivity -New class of drugs offer alternative to #statins -Sandoz #CEO Richard Francis to step down Last week's TOP 10 http://bit.ly/2O6DJ2e  #ph

-23andMe to offer genetic reports on #diabetes -Dutch pharmacists dodge #Novartis #cancer drug market exclusivity -New class of drugs offer alternative to #statins -Sandoz #CEO Richard Francis to step down Last week's TOP 10 http://bit.l

Report: TB Could Be Conquered by 2045

(MedPage Today) -- It's within the world's means to end ancient scourge

Gerresheimer AG: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]

Gerresheimer AG / Preliminary announcement on the disclosure of financial statements 20.03.2019 / 18:24 Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act] transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. ---------------------------------...

FDA puts multiple myeloma trial on hold after patient deaths http://bit.ly/2U5oA6V  #cancer #oncology #clinicaltrials

FDA puts multiple myeloma trial on hold after patient deaths http://bit.ly/2U5oA6V  #cancer #oncology #clinicaltrials

Roche's Tecentriq chalks up another FDA approval, this time in first-line extensive-stage small cell #LungCancer http://bit.ly/2UKqF5h  #cancer

Roche's Tecentriq chalks up another FDA approval, this time in first-line extensive-stage small cell #LungCancer http://bit.ly/2UKqF5h  #cancer


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks